(2002). Accelerated apoptotic DNA laddering protocol. Biotechniques
(1995). AH: Cell death in health and disease: the biology and regulation of apoptosis. Semin Cancer Biol
(1995). Apoptosis, oncosis, and necrosis: an overview of cell death.
(1998). Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein.
(1999). Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res
(1998). Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR a protein in acute promyelocytic leukemia cells.
(1999). Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett
(2003). Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2. Mol Cancer Ther
(1999). Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression.
(1999). Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood
(2009). Biological responses to arsenic compounds.
(2000). Bootman MD: The versatility and universality of calcium signaling. Nat Rev Mol Cell Biol
(2003). Cell death induced by acute renal injury: a perspective on the contributions of apoptosis and necrosis.
(2002). CJ: Involvement of reactive oxygen species in arsenite-induced downregulation of phospholipid hydroperoxide glutathione peroxidase in human epidermoid carcinoma A431 cells. Free Radic Biol Med
(1999). de Thé H: Arsenic trioxide and interferon- synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999, 93:278-273. Yedjou et al.
(1994). Death from inside out: an overview.
(1993). Eigenbrodt EH: Apoptosis and necrosis. Basic types and mechanisms of cell death. Arch Pathol Lab Med
(2000). F: Flow cytometry detection of caspase 3 activation in preapoptotic leukemic cells. Cytometry
(1999). Fermand JP: Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res
(1998). JK: Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis.
(2000). Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res
(2001). Necrotic volume increase and the early physiology of necrosis. Comp Biochem Physiol A
(1994). Oers MH: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood
(1998). Pandolfi PP: Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML/RAR- independent manner. Blood
(2005). PM: Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia.
(1995). Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V.
(1998). RP: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
(1996). SH: The role of proteases during apoptosis.
(2002). SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell
(2010). Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet
(1997). Tatton WG: Mechanisms of nerve cell death: apoptosis or necrosis after cerebral ischemia. Int Rev Neurobiol
(2009). Tchounwou PB: Arsenic trioxide-induced modulation of p53, c-fos, RARE, cyclin D1, and cyclin A in human leukemia (HL-60) cells. Mol Cell Biochem
(2009). Tchounwou PB: Ascorbic acid potentiation of arsenic trioxide anticancer activity against acute promyelocytic leukemia. Archives of Drug Information
(2008). Tchounwou PB: Differential effect of ascorbic acid and n-acetyl-l-cysteine on arsenic trioxide-mediated oxidative stress in human leukemia (HL-60) cells.
(2006). Tchounwou PB: Dose and time-dependent response of human acute promyelocytic leukemia (HL-60) cells to arsenic trioxide treatment.
(2007). Tchounwou PB: In vitro cytotoxic and genotoxic effects of arsenic trioxide on human leukemia (HL-60) cells using the MTT and alkaline single cell gel electrophoreis (comet) assays. Mol Cell Biochem
(2006). Tchounwou PB: Oxidative stress in human leukemia (HL-60), human liver carcinoma (HepG2), and human Jurkat-T cells exposed to arsenic trioxide. Metal Ions Biol Med
(1975). Therapeutic mule: the use of arsenic in the nineteenth century material medica. Pharmacy in History
(2000). Ying DM: Arsenic trioxide induced apoptosis of the human B lymphoma cell line MBC-1. J Biol Regulat Homeost Agent
(2000). YY: Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res
(1996). Z: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR/PML proteins. Blood